Working... Menu

Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma (IPi-504-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00113204
Recruitment Status : Completed
First Posted : June 7, 2005
Last Update Posted : May 20, 2008
Information provided by:
Infinity Pharmaceuticals, Inc.

Brief Summary:
This is a phase 1 clinical trial to find the safe, maximum tolerated dose of IPI-504 in patients with relapsed and/or relapsed, refractory multiple myeloma. This study will examine how IPI-504 is absorbed, distributed, metabolized, and eliminated by the body. The study will also evaluate potential anti-tumor activity of IPI-504.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: IPI-504 Phase 1

Detailed Description:
IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90), an emerging and recently identified target for cancer therapy. Hsp90 is a protein chaperone that plays a central role in regulating protein homeostasis. Hsp90 regulates the stability of key proteins (called "client proteins") and keeps them in the appropriate three dimensional shape so they can perform their cellular functions. In addition, many of the proteins stabilized by Hsp90 are oncoproteins and cell-signaling proteins important in cancer cell proliferation and cancer cell survival. Thus Hsp90, a single molecular target that is a central integrator of multiple pathways important to cancer, is an ideal novel target for oncologic therapy. Selective inhibition of Hsp90 will affect multiple downstream mechanisms to disrupt tumor growth and selectively kill cancer cells. The anti-neoplastic effects of Hsp90 inhibition have been demonstrated both in vitro and in vivo for a variety of different hematologic and solid tumors including multiple myeloma.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Safety Assessment and Pharmacokinetic Study of IPI-504 in Patients With Relapsed, and Relapsed Refractory Multiple Myeloma
Study Start Date : June 2005
Actual Primary Completion Date : March 2007
Actual Study Completion Date : March 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Primary Outcome Measures :
  1. To determine the safety and maximum tolerated dose of IPI-504 [ Time Frame: Following 1 cycle of treatment ]
  2. Recommend a dose for subsequent studies of IPI-504 [ Time Frame: Once MTD is reached ]

Secondary Outcome Measures :
  1. To examine the pharmacokinetic parameters of IPI-504 [ Time Frame: During first dose first cycle of IPI-504 ]
  2. To evaluate the potential anti-tumor activity with standard markers of disease progression [ Time Frame: 1 cycle of treatment ]
  3. To examine pharmacodynamic markers of biologic activity of IPI-504 [ Time Frame: Cycle 1 of treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of relapsed or relapsed, refractory disease
  • Age is greater or equal to 18 years at the time of signing the informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • Ability to adhere to the study visit schedule and all protocol requirements
  • Voluntarily sign an informed consent
  • All baseline studies must be completed for determining eligibility within 21 days of study enrollment
  • Women of child-bearing potential (WCBP) defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally post-menopausal for at least 24 consecutive months must have a negative serum or urine pregnancy test prior to each cycle of treatment
  • All WCBP and all sexually active male patients must agree to use adequate methods of birth control throughout the study

Exclusion Criteria:

  • Disease specific treatment within the previous 3 weeks including use of chemotherapy that is known to be active or may be active against multiple myeloma
  • Previous treatment with 17-AAG, DMAG, or other known Hsp90 inhibitor
  • Participation in any investigational drug study within 3 weeks preceding start of treatment for conventional small molecule therapy or 4 weeks preceding the start of treatment for biologic or vaccine therapy; concurrent radiation therapy is not permitted
  • Concomitant use of corticosteroids may not exceed prednisone 10 mg per day with the exception of pre-medication for transfusion of blood products and topical application
  • Concurrent treatment with any agent that alters CYP3A activity (unless maintained on stable dose)
  • Baseline QTc >450
  • NYHA class 3 or 4 congestive heart failure
  • Left Bundle Branch Block
  • Mycardial infarction or active ischemic heart disease within 6 months
  • Grade 3 or greater peripheral neuropathy
  • Renal insufficiency, serum creatinine >2x upper limit of normal (ULN)
  • Platelets < 30,000 mm3 or refractory to transfusion and unable to be maintained > 50,000 mm3
  • AST and / or ALT > 2.0x ULN
  • ANC <1,000 cells/mm3
  • Hemoglobin < 8.0 g/dL
  • Presence of active infection or systemic use of antibiotics within 72 hours of treatment
  • WCBP who are breast feeding
  • Significant co-morbid condition or disease which in the judgment of the investigator would place the patient at undue risk or interfere with the study (e.g. cardiac disease such as acute coronary syndrome or unstable angina within 6 months, New York Heart Association (NYHA) class 2 or greater congestive heart failure (CHF), uncontrolled hypertension, arrhythmia requiring medication or mechanical control, chronic obstructive pulmonary disease (COPD), cirrhotic liver disease, or other conditions)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00113204

Layout table for location information
United States, Maryland
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, United States, 21231
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, New Jersey
Hackensack University Medical Center The David Jurist Research Center
Hackensack, New Jersey, United States, 07601
United States, New York
St. Vincent's Comprehensive Cancer Center
New York, New York, United States, 10011
Sponsors and Collaborators
Infinity Pharmaceuticals, Inc.
Layout table for investigator information
Principal Investigator: Sundar Jagannath, MD St. Vincent's Comprehensive Cancer Center
Principal Investigator: David S. Siegel, MD; Ph.D Hackensack Meridian Health
Principal Investigator: Ivan Borrello, MD Johns Hopkins - Sidney Kimmel Comprehensive Cancer Center
Principal Investigator: Paul Richardson, MD Dana-Farber Cancer Institute

Additional Information:
Layout table for additonal information Identifier: NCT00113204     History of Changes
Other Study ID Numbers: IPI-504-01
First Posted: June 7, 2005    Key Record Dates
Last Update Posted: May 20, 2008
Last Verified: May 2008

Keywords provided by Infinity Pharmaceuticals, Inc.:
Multiple myeloma
Relapsed refractory
Hematologic cancer
hematologic disease
plasma cells

Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases